A Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 19, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions

Her2-positive/Low-expression Urinary and Digestive Tract Tumors

Interventions

DRUG

BL-M07D1

BL-M07D1 was administered by intravenous infusion every 3 weeks in 3-week cycles.

Trial Locations (1)

RECRUITING

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors

lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY